NONE, BUT I SHOULD GET SOME

Similar documents
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Best Medical Treatments for Parkinson s disease

What s new for diagnosing and treating Parkinson s Disease?

Key Concepts and Issues in Parkinson s Disease in 2016

Optimizing Clinical Communication in Parkinson s Disease:

Parkinson s Disease Current Treatment Options

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

10th Medicine Review Course st July Prakash Kumar

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Commonly encountered medications and their side effects - what the generalist needs to know

Medications used to treat Parkinson s disease

Evaluation and Management of Parkinson s Disease in the Older Patient

Parkinson s Disease Medications: Professionals Edition

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Faculty Information 2/15/2013

Appendix 2: Admissions checklists for people with Parkinson s

Parkinson s Disease. Gillian Sare

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Acute management of in-patient Parkinson s Disease patients

Medicines Management and the Unwell Parkinson s Patient

Drugs for Parkinson s Disease

The Fresco Institute for Parkinson's and Movement Disorders

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

10/4/2016. Disclosures. Motor symptoms are Just the tip of the iceberg. Parkinson s Disease for the Primary Care Clinician

Clinical Guideline for the management of inpatients with Parkinson s disease

Parkinson s Disease and Treatment Options for the Younger Adult

Parkinson s Disease and Treatment Options for the Younger Adult

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

PD: Key Treatment Considerations

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

PARKINSON S MEDICATION

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

What is Parkinson s Disease?

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Faculty. Joseph Friedman, MD

PL CE LIVE July 2015 Forum

Parkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

Disclosures. Objectives. What s Shaking? Tremors and Movement Disorders

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Tremor, Rigidity, Tics and Dystonia: The 4 Most Common Movement Disorders

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

Medication Management & Strategies When the levodopa honeymoon is over

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Literature Scan: Anti-Parkinson s Agents

Parkinson s Pharmacology

Communicating About OFF Episodes With Your Doctor

Welcome and Introductions

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Any interventions, where RCTs in PD are not available, are not included in the tables.

Movement Disorders: A Brief Overview

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

NMG-NEUROLOGY Dr. Bega, Dr. Malkani, Dr. Melen, Dr. Opal, Dr. Simuni, and Dr. Zadikoff MEDICAL BACKGROUND AND INFORMATION FORM

Movement Disorders. Eric Kraus, MD! Neurology!

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Treatment of Parkinson s Disease: Present and Future

Parkinson s Disease Update

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC

Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017

Welcome and Introductions

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

Alison Charleston 1 st September 2016

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Huntington s Disease

Clinical Features and Treatment of Parkinson s Disease

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

XADAGO (safinamide) oral tablet

Parkinson's Disease and how you can make a difference with medication

Update in the Management of Parkinson s Disease

Management of Neurological Conditions at End of Life

An Overview of Parkinson s Medication used in Multiple System Atrophy

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

The Shaking Palsy of 1817

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Disclosures. Objectives. What s Shaking? Tremors and Movement Disorders

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

Christopher J. Earley, MB, BCh, PhD Professor Department of Neurology Johns Hopkins School of Medicine

Welcome and Introductions

Transcription:

Ma#hew West, MD Assistant Professor Department of Neurology University of Colorado NONE, BUT I SHOULD GET SOME Discuss the effect of Parkinson s Disease on mulmple organ systems Review medicamon management for symptoms in the post- operamve phase Review Parkinson s Disease medicamons, specifically their importance in the post- operamve course

The Shaking Man Terry Allen, 1993 78 year old man diagnosed with Parkinson s disease (PD) 12 years ago presents awer mechanical fall, resulmng in a distal femur fracture requiring internal fixamon surgery. Current PD medicamon regimen is: 1. Carbidopa/levodopa 25mg/100mg 5 Mmes per day 2. Entacapone 200 mg 5 Mmes per day 3. Pramipexole 1 mg 3 Mmes per day 4. Amantadine 100 mg oral twice a day WHY SHOULD WE CARE? Increased risk of nosocomial morbidity Post- operamve stays are longer than non- PD 18 days versus 14.5 days (Mueller, 2009) 11.4 days versus 8.8 days (Pepper, 1999) Overall duramon of inpament treatment significantly longer 21.4 days versus 18.2 days (Mueller, 2009) Trend towards higher inpament mortality 7.3% versus 3.8% (Pepper, 1999) Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511 Pepper, et al. J Am Geriatric Soc. 1999;47(8):967

Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511

Increased risk of post- operamve falls LimitaMons in rehabilitamon Mueller, et al Lagngerbecks Arch Surg 2009;394(3):511 RECOMMENDATIONS Early and aggressive PT/OT Fall precaumons Early reinimamon of parkinson s medicamons

Can have obstrucmve or restricmve pa#ern on PFTs Increased airway resistance and decrease lung elasmc recoil lead to OBSTRUCTIVE pa#ern Rigidity of chest wall and upper airway muscles can lead to RESTRICTIVE pa#ern Pneumonia remains leading cause of mortality among PD paments Increase aspira&on risk in perioperamve period OR 3.825, p<0.001 (Pepper, 1999) Shill et al, Clin Neurosci 1998;5(2):131-135 Pepper, et al. J Am Geriatric Soc. 1999;47(8):967 RECOMMENDATIONS AspiraMon PrecauMons Swallow evaluamon early in course Inspiratory Spirometer (IS) Pulmonary Toilet Early mobilizamon Early reinimamon of parkinson s medicamons SecreMons SucMoning Glycopyrrolate 1 mg PO TID (Arbouw, Neurology 2010) Arbouw, et al. Neurology 2010;74(15):1203-7

Dysphagia is common in PD 50-80% on barium swallow examinamons (Castell, 2001) Secondary to abnormality of muscles in mouth, pharynx, and esophagus Increase risk of aspiramon and malnutrimon GI DysmoMlity Due to Lewy Body deposimon in Myenteric Plexus ConsMpaMon Gastroparesis Ileus Castell, et al. Neurogastroenterol Motil 2001;13(4):361-64 RECOMMENDATIONS Swallow evaluamon! Consider pre- operamve swallow evaluamon AspiraMon precaumons Monitor nutrimon closely Aggressive bowel regimen (smmulant and sowener) MobilizaMon Early reinimamon of parkinson s medicamons Avoid anm- cholinergics if possible GASTROPARESIS: Erythromycin NOT Metoclopramide

OrthostaMc hypotension Post- prandial hypotension Impaired heart rate (HR) variability Risk of arrhythmias with pro- dopaminergic medicamons Katus, et al. American Journal Medicine 2014;127:275-80 RECOMMENDATIONS Fall precaumons Check orthostamcs as necessary Change of posimon slowly CauMon with beta- blockers and other nodal medicamons If have orthosta&c hypotension Adequate hydramon Head- of- bed when sleeping 30-45 degrees Thigh high compression stockings If severe orthostasis!abdominal binder MedicaMon opmons FludrocorMsone 0.1-0.3 mg oral daily Midodrine 10 mg 3 Mmes per day during daymme

About one- third PD paments have demenma AddiMonal one- quarter to one- third have mild cognimve impairment (MCI) High risk of post- operamve delirium OR 2.6 versus controls (Pepper, 1999) Aarsland D, et al. Mov Disord. 2005;20(10):1255 Pepper, et al. J Am Geriatric Soc. 1999;47(8):967 RECOMMENDATIONS Delirium precaucons " Sleep/wake cycle " Hydra&on/nutri&on MedicaCons (for PD) AnMcholinergics>>Amantadine/Dopamine Agonists>>Levodopa/MAOI- B worsen delirium If need pharmacologic restraint AVOID typical anmpsychomcs (e.g., Haldol) CauMon with atypical anm- psychomcs QueCapine and Clozapine have low dopamine- blockade and are owen used

Undergoes successful surgery Complaining of pain in post- operamve period that is appropriately addressed Develops nausea/vomimng, cross- cover physician writes for an anm- ememc On your next examinamon, you note worsening rigidity and tremor Why? What medicacon may have been given? An#- eme#cs with dopamine (D2) blockade Metoclopramide Prochlorperazine Promethazine USE INSTEAD: Ondansetron An#- psycho#cs with high D2 blockade Typical antipsychotics Most atypical antipsychotics USE INSTEAD: Quetiapine Clozapine If on MAO- B inhibitor (selegiline, rasagiline) Cau&on with Meperidine Tramadol Methadone Dextromethorphan New SSRI, SNRI, and TCAs

Over the next 3 days, the pament declines clinically: Consciousness level worsens Unable to follow commands Becomes febrile to 40.2 Fluctuating heart rate Tone increased axially and in all four limbs Develops leukocytosis and elevated CK (9,000) What happened and what should be done? Similar to NeurolepMc Malignant Syndrome (NMS) Occurs about 3-4 days awer cessamon/decrease of dopaminergic medicamons Signs/symptoms High fever Muscle rigidity Autonomic instability Altered mental status (reduced consciousness) Complications Acute kidney injury Rhabdomyolysis Disseminated intravascular coagulamon Pro- Dopaminergic Carbidopa/Levodopa (Sinemet ) Dopamine Agonists Pramipexole (Mirapex ) Ropinirole (Requip ) Rotigotine (Neupro patch ) Amantadine MAO- B Inhibitors Selegiline (Eldepryl, Zelapar ) Rasagiline (Azilect ) AnC- cholinergics Trihexyphenidyl (Artane ) COMT inhibitor Entacapone (Comtan ) Tolcapone (Tasmar )

Start pacent s PD regimen ASAP! As close to home regimen as possible Pay azencon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night

Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Carbidopa/Levodopa Similar efficacy to convenconal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Affects Levodopa absorpmon Consider bolused tube feeds or starmng at night Start pament s PD regimen ASAP! As close to home regimen as possible Pay a#enmon to dose and TIMES Consider NG- tube if unable to take PO Consider Parcopa Oral- dissolvable Similar efficacy to convenmonal Levodopa Dosing similar to home Carbidopa/Levodopa Tube feedings Effects Levodopa absorpcon Consider bolused tube feeds or starcng at night In post- operamve seong, Parkinson s Disease can have impact on mulmple organ systems Important to avoid medicamons that may worsen their disease Start pament on home parkinson s regimen as soon as possible Low threshold to consult Neurology colleagues!